转移性前列腺癌中靶向前列腺特异性膜抗原的放射性配体疗法：近期证据的综合分析 - Suppr | 超能文献

PSMA-targeted radioligand therapy in metastatic prostate cancer: Comprehensive analysis of recent evidence.

作者信息

Petranović Ovčariček Petra, Garo Maria Luisa, Giovanella Luca

机构信息

Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, 10000, Croatia.

School of Medicine, University of Zagreb, Zagreb, 10000, Croatia.

出版信息

Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1242-1245. doi: 10.1007/s00259-024-07041-w.

DOI:10.1007/s00259-024-07041-w

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

PSMA-targeted radioligand therapy in metastatic prostate cancer: Comprehensive analysis of recent evidence.转移性前列腺癌中靶向前列腺特异性膜抗原的放射性配体疗法：近期证据的综合分析

Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1242-1245. doi: 10.1007/s00259-024-07041-w.

2

Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer.镥-PSMA-617放射性配体疗法治疗一名淋巴结转移性前列腺癌患者。

Oncotarget. 2017 Aug 2;8(39):66112-66116. doi: 10.18632/oncotarget.19805. eCollection 2017 Sep 12.

3

A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.镥-177 标记前列腺特异性膜抗原靶向放射性配体治疗在转移性去势抵抗性前列腺癌中的疗效和毒性的系统评价和荟萃分析。

Eur Urol. 2021 Jul;80(1):82-94. doi: 10.1016/j.eururo.2021.03.004. Epub 2021 Apr 8.

4

Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.镥-177 标记 PSMA 配体治疗转移性去势抵抗性前列腺癌的疗效和生存的真实世界数据分析。

Target Oncol. 2021 May;16(3):369-380. doi: 10.1007/s11523-021-00801-w. Epub 2021 Mar 9.

5

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer.镥-177标记的前列腺特异性膜抗原-617用于前列腺癌的分子成像和靶向放射性配体治疗

Adv Pharm Bull. 2023 Nov;13(4):701-711. doi: 10.34172/apb.2023.079. Epub 2023 Apr 29.

6

Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.关于[177Lu]Lu-PSMA-617靶向放射性配体疗法治疗转移性去势抵抗性前列腺癌的部分已完成前瞻性研究综述。

Rofo. 2025 Jan 22. doi: 10.1055/a-2514-4523.

7

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials.前列腺癌中靶向前列腺特异性膜抗原（PSMA）的放射性配体疗法现状：当前数据与未来试验

Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157632. doi: 10.1177/17588359231157632. eCollection 2023.

8

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen.使用分子靶向疗法治疗晚期转移性前列腺癌：放射性配体镥-177前列腺特异性膜抗原

Cureus. 2023 Apr 18;15(4):e37778. doi: 10.7759/cureus.37778. eCollection 2023 Apr.

9

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer.叙述性综述：转移性去势抵抗性前列腺癌的前列腺特异性膜抗原放射性配体疗法

Transl Androl Urol. 2021 Oct;10(10):3963-3971. doi: 10.21037/tau-20-1135.

10

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials.177镥-PSMA-617放射性配体疗法在前列腺癌治疗中的应用：文献综述与正在进行的试验

Discov Oncol. 2024 Dec 18;15(1):791. doi: 10.1007/s12672-024-01680-z.

引用本文的文献

1

Efficacy of Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response.Lu-PSMA-617疗法在伴有肝转移的去势抵抗性前列腺癌患者中的疗效：生存结果及反应预测因素分析

Biomedicines. 2025 Feb 24;13(3):569. doi: 10.3390/biomedicines13030569.